MammoSite multilumen catheter: Dosimetry considerations

Ravi, A.; Lee, Susan; Karsif, Karen; Osian, Adrian; Nori, Dattatreyudu

doi:10.4103/0973-1482.80469

Cited by 7 publications

(3 citation statements)

References 9 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there are contraindications that can interfere with dosage planning ( 34 ) : insufficient distance between the tumor and the skin; and an extensive cavity. Its use is not indicated when the tumor cavity is in an area of tissue that cannot be sufficiently covered ( 35 ) . Undesirable anatomic surgical conditions and ineligible histological conditions can also preclude the application of the balloon technique ( 17 ) .…”

Section: Discussionmentioning

confidence: 99%

Balloon-based adjuvant radiotherapy in breast cancer: comparison between 99mTc and HDR 192Ir

2016

View full text Add to dashboard Cite

ObjectiveTo perform a comparative dosimetric analysis, based on computer simulations, of temporary balloon implants with 99mTc and balloon brachytherapy with high-dose-rate (HDR) 192Ir, as boosts to radiotherapy. We hypothesized that the two techniques would produce equivalent doses under pre-established conditions of activity and exposure time.Materials and MethodsSimulations of implants with 99mTc-filled and HDR 192Ir-filled balloons were performed with the Siscodes/MCNP5, modeling in voxels a magnetic resonance imaging set related to a young female. Spatial dose rate distributions were determined. In the dosimetric analysis of the protocols, the exposure time and the level of activity required were specified.ResultsThe 99mTc balloon presented a weighted dose rate in the tumor bed of 0.428 cGy.h-1.mCi-1 and 0.190 cGyh-1.mCi-1 at the balloon surface and at 8-10 mm from the surface, respectively, compared with 0.499 and 0.150 cGyh-1.mCi-1, respectively, for the HDR 192Ir balloon. An exposure time of 24 hours was required for the 99mTc balloon to produce a boost of 10.14 Gy with 1.0 Ci, whereas only 24 minutes with 10.0 Ci segments were required for the HDR 192Ir balloon to produce a boost of 5.14 Gy at the same reference point, or 10.28 Gy in two 24-minutes fractions.ConclusionTemporary 99mTc balloon implantation is an attractive option for adjuvant radiotherapy in breast cancer, because of its availability, economic viability, and similar dosimetry in comparison with the use of HDR 192Ir balloon implantation, which is the current standard in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Balloon-based adjuvant radiotherapy in breast cancer: comparison between 99mTc and HDR 192Ir

2016

View full text Add to dashboard Cite

show abstract

“…This unique study enabled direct comparison between the dosimetric capabilities of the single-lumen and ML-MS catheters by using the same patient cohort. Previous studies comparing single-lumen and ML balloon catheters were carried out on different patient cohorts and used the Contura multilumen balloon (SenoRx Inc., Irvice, CA) (10e13), other than that of Ravi et al (14) who used the ML-MS catheter on 2 patients.…”

Section: Introductionmentioning

confidence: 99%

Optimization and comparison of balloon-based partial breast brachytherapy using a single source, a standard plan line source, and both forward and inverse planned multilumen techniques

et al. 2013

View full text Add to dashboard Cite

“…1 For APBI brachytherapy, there are still many choices available, such as low-dose rate versus high-dose rate (HDR), difference devices (balloon types), difference sources 1 Radiation Oncology, Saint Vincent's Medical Center, Bridgeport, CT, USA (electrons vs photons), or timing (intraoperative vs after surgery). 3,4 Previous studies have been done extensively to cover the APBI brachytherapy simulation device selection and comparison, 5,6 treatment planning concerns, 7-10 treatment toxicity, [11][12][13][14][15][16] and clinical outcomes. [17][18][19][20][21][22][23][24][25][26][27][28] However, with the increasing usage of APBI brachytherapy 1 and safety concerns 29,30 for brachytherapy, it is vital to have a single-community hospital experience, which will still be able to help the society to understand APBI brachytherapy treatment safety implementation, clinical outcomes, and help to confirm known results.…”

Section: Introductionmentioning

confidence: 99%

A Single-Site Retrospective, Nonrandomized Study of Accelerated Partial Breast Irradiation Brachytherapy for Early-Stage Breast Cancer Treatment to Evaluate Local Tumor Control, Cosmetic Outcome, and Toxicities

Shah

Holzwanger

Khwaja

et al. 2016

Technol Cancer Res Treat

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy and safety of the accelerated partial breast irradiation brachytherapy with a combination of applicators at a community hospital cancer center. Methods and Materials: Between 2005 and 2009, 120 patients with early-stage breast cancer were being followed after treatment with accelerated partial breast irradiation brachytherapy using MammoSite, single or multilumen balloon, or Contura multilumen balloon. After their lumpectomy surgery, each patient was treated with Ir-192 high-dose rate unit following radiation therapy oncology group 0413 guidelines. The patients had multiple follow-ups at 6 months, 1 year, 2 years, 3 years, or more. Results: Based on the Harvard Breast Cosmesis Scale, 95.00% of patients described their cosmetic evaluation as the treated breast essentially the same as the opposite side (excellent) or minimal but identifiable effects were noticed from radiation (good). After a median follow-up of 36 months, the local recurrence rate was 1.66% and a disease-free survival is 98.3%. Forty-two patients reported 85 adverse events, which were fibrosis: 24.70%, hyperpigmentation: 20.00%, radiation skin reaction: 7.05%, seroma: 7.05%, breast pain: 7.05%, erythema: 5.88%, and other events were less than 5.00%. Of all the adverse events recorded, grade 1 to 3 events are 95.29% (n ¼ 81), 2.35% (n ¼ 2), and 2.35% (n ¼ 2). There was no grade 4 or 5 events recorded. Conclusions: Our study has shown promising results for delivering radiation with MammoSite, single or multilumen balloon, or Contura multilumen balloon and has been successful in achieving local control in patients with early-stage breast cancer.

show abstract

MammoSite multilumen catheter: Dosimetry considerations

Cited by 7 publications

References 9 publications

Balloon-based adjuvant radiotherapy in breast cancer: comparison between 99mTc and HDR 192Ir

Balloon-based adjuvant radiotherapy in breast cancer: comparison between 99mTc and HDR 192Ir

Optimization and comparison of balloon-based partial breast brachytherapy using a single source, a standard plan line source, and both forward and inverse planned multilumen techniques

A Single-Site Retrospective, Nonrandomized Study of Accelerated Partial Breast Irradiation Brachytherapy for Early-Stage Breast Cancer Treatment to Evaluate Local Tumor Control, Cosmetic Outcome, and Toxicities

Contact Info

Product

Resources

About